Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the launch of NEW CentoGenome®, an enhanced Next
Generation Sequencing (NGS)-based assay. Healthcare professionals
can leverage NEW CentoGenome to provide more comprehensive
diagnostic information, which could accelerate access to potential
treatment options.
Serving as a first-line test, NEW CentoGenome is the most
comprehensive commercially available Whole Genome Sequencing (WGS)
test on the market for both rare and neurodegenerative disorders –
covering almost all disease-causing variants, including the most
relevant repeat expansions associated with neurological diseases,
in a single assay. NEW CentoGenome also detects Copy Number
Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), as
well as complex disease-causing variants associated with Gaucher
Disease (GD) and susceptibility to GBA1-related Parkinson's Disease
(PD), with the highest levels of sensitivity.
The newly designed WGS assay leverages a Polymerase Chain
Reaction (PCR)-free approach. This significantly diminishes the
typical bias induced by PCR and provides higher quality sequencing
data across the typically challenging regions of the genome by
enabling more uniform coverage and superior performance in variant
detection.
“As a pioneer of genetic diagnostics, we are committed to
enabling access to high-quality diagnostics and ensuring that
cutting-edge data analyses are available to support better patient
health outcomes,” said Prof. Peter Bauer, Chief Medical and Genomic
Officer at CENTOGENE. “Building on this expertise, CENTOGENE’s
enhanced whole genome sequencing is the leading solution on the
market, reflecting the latest advanced technologies and unique
insights that can’t be found anywhere else to provide maximized
disease coverage. Ultimately, this will provide physicians with an
unparalleled level of certainty when diagnosing, prognosing, and
treating patients.”
CENTOGENE’s NEW CentoGenome - Superior Technology With
Market-Leading Clinical Coverage in a Single Test
CENTOGENE’s enhanced WGS solution consists of three seamlessly
integrated key features:
Advanced Technology for Greater Insights
- Implementing PCR-free technology to
significantly reduce bias and provide high-quality sequencing
information for difficult-to-sequence genetic regions – enabling
greater insights into coding, regulatory, and intronic regions
Superior Performance for Enhanced Disease
Coverage
- Delivering superior performance in
variant detection thanks to CENTOGENE’s automated CE-IVD
bioinformatics pipeline and medical expert-based analysis of the
CENTOGENE Biodatabank, which consists of approximately 700,000
patients representing over 120 highly diverse countries
Integrated Variant Reclassification and Confirmatory
Testing for a Life-Long Commitment to Patients
- Demonstrating CENTOGENE’s unique
commitment to improving the lives of patients with rare and
neurodegenerative diseases, NEW CentoGenome is paired with
life-long diagnostic support and a free-of-charge and proactive
diagnosis confirmation and reclassification program
To find out more about NEW CentoGenome, visit:
https://link.centogene.com/WGS
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
CENTOGENE
Ben Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024